Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group

Next-Generation Sequencing is needed for the accurate genetic risk stratification of acute myeloid leukemia according to European LeukemiaNet (ELN) guidelines. We validated and compared the 2022 ELN risk classification in a real-life cohort of 546 intensively and 379 non-intensively treated patients...

ver descrição completa

Detalhes bibliográficos
Autores: Sargas, C, Ayala, R, Larrayoz, MJ, Chillon, MC, Rodriguez-Arboli, E, Bilbao, C, de la Torre, EP, Martinez-Cuadron, D, Rodriguez-Veiga, R, Boluda, B, Gil, C, Bernal, T, Bergua, J, Algarra, L, Tormo, M, Martinez-Sanchez, P, Soria, E, Serrano, J, Alonso-Dominguez, JM, Garcia, R, Amigo, ML, Herrera-Puente, P, Sayas, MJ, Lavilla-Rubira, E, Martinez-Lopez, J, Calasanz, MJ, Garcia-Sanz, R, Perez-Simon, JA, Casares, MTG, Sanchez-Garcia, J, Barragan, E, Montesinos, P
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2023
País:España
Recursos:Instituto de Investigación Biomédica y Sanitaria de Alicante (ISABIAL)
Repositorio:r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
OAI Identifier:oai:isabial.fundanetsuite.com:p9741
Acesso em linha:https://isabial.portalinvestigacion.com/publicaciones9741
https://www.nature.com/articles/s41408-023-00835-5
Access Level:acceso abierto
id ES_bab6cd3bbbdd3ecb3275821c2b01b504
oai_identifier_str oai:isabial.fundanetsuite.com:p9741
network_acronym_str ES
network_name_str España
repository_id_str
spelling Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA groupSargas, CAyala, RLarrayoz, MJChillon, MCRodriguez-Arboli, EBilbao, Cde la Torre, EPMartinez-Cuadron, DRodriguez-Veiga, RBoluda, BGil, CBernal, TBergua, JAlgarra, LTormo, MMartinez-Sanchez, PSoria, ESerrano, JAlonso-Dominguez, JMGarcia, RAmigo, MLHerrera-Puente, PSayas, MJLavilla-Rubira, EMartinez-Lopez, JCalasanz, MJGarcia-Sanz, RPerez-Simon, JACasares, MTGSanchez-Garcia, JBarragan, EMontesinos, PNext-Generation Sequencing is needed for the accurate genetic risk stratification of acute myeloid leukemia according to European LeukemiaNet (ELN) guidelines. We validated and compared the 2022 ELN risk classification in a real-life cohort of 546 intensively and 379 non-intensively treated patients. Among fit patients, those aged >= 65 years old showed worse OS than younger regardless risk classification. Compared with the 2017 classification, 14.5% of fit patients changed the risk with the 2022 classification, increasing the high-risk group from 44.3% to 51.8%. 3.7% and 0.9% FLT3-ITD mutated patients were removed from the favorable and adverse 2017 categories respectively to 2022 intermediate risk group. We suggest that midostaurin therapy could be a predictor for 3 years OS (85.2% with vs. 54.8% without midostaurin, P = 0.04). Forty-seven (8.6%) patients from the 2017 intermediate group were assigned to the 2022 adverse-risk group as they harbored myelodysplasia (MDS)-related mutations. Patients with one MDS-related mutation did not reach median OS, while patients with >= 2 mutations had 13.6 months median OS (P = 0.002). Patients with TP53 +/- complex karyotype or inv(3) had a dismal prognosis (7.1 months median OS). We validate the prognostic utility of the 2022 ELN classification in a real-life setting providing supportive evidences to improve risk stratification guidelines.SPRINGERNATURE2023info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://isabial.portalinvestigacion.com/publicaciones9741https://www.nature.com/articles/s41408-023-00835-5Blood Cancer JournalISSN: 20445385reponame:r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicanteinstname:Instituto de Investigación Biomédica y Sanitaria de Alicante (ISABIAL)Inglésinfo:eu-repo/semantics/openAccessoai:isabial.fundanetsuite.com:p97412026-06-12T10:20:37Z
dc.title.none.fl_str_mv Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group
title Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group
spellingShingle Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group
Sargas, C
title_short Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group
title_full Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group
title_fullStr Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group
title_full_unstemmed Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group
title_sort Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group
dc.creator.none.fl_str_mv Sargas, C
Ayala, R
Larrayoz, MJ
Chillon, MC
Rodriguez-Arboli, E
Bilbao, C
de la Torre, EP
Martinez-Cuadron, D
Rodriguez-Veiga, R
Boluda, B
Gil, C
Bernal, T
Bergua, J
Algarra, L
Tormo, M
Martinez-Sanchez, P
Soria, E
Serrano, J
Alonso-Dominguez, JM
Garcia, R
Amigo, ML
Herrera-Puente, P
Sayas, MJ
Lavilla-Rubira, E
Martinez-Lopez, J
Calasanz, MJ
Garcia-Sanz, R
Perez-Simon, JA
Casares, MTG
Sanchez-Garcia, J
Barragan, E
Montesinos, P
author Sargas, C
author_facet Sargas, C
Ayala, R
Larrayoz, MJ
Chillon, MC
Rodriguez-Arboli, E
Bilbao, C
de la Torre, EP
Martinez-Cuadron, D
Rodriguez-Veiga, R
Boluda, B
Gil, C
Bernal, T
Bergua, J
Algarra, L
Tormo, M
Martinez-Sanchez, P
Soria, E
Serrano, J
Alonso-Dominguez, JM
Garcia, R
Amigo, ML
Herrera-Puente, P
Sayas, MJ
Lavilla-Rubira, E
Martinez-Lopez, J
Calasanz, MJ
Garcia-Sanz, R
Perez-Simon, JA
Casares, MTG
Sanchez-Garcia, J
Barragan, E
Montesinos, P
author_role author
author2 Ayala, R
Larrayoz, MJ
Chillon, MC
Rodriguez-Arboli, E
Bilbao, C
de la Torre, EP
Martinez-Cuadron, D
Rodriguez-Veiga, R
Boluda, B
Gil, C
Bernal, T
Bergua, J
Algarra, L
Tormo, M
Martinez-Sanchez, P
Soria, E
Serrano, J
Alonso-Dominguez, JM
Garcia, R
Amigo, ML
Herrera-Puente, P
Sayas, MJ
Lavilla-Rubira, E
Martinez-Lopez, J
Calasanz, MJ
Garcia-Sanz, R
Perez-Simon, JA
Casares, MTG
Sanchez-Garcia, J
Barragan, E
Montesinos, P
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
description Next-Generation Sequencing is needed for the accurate genetic risk stratification of acute myeloid leukemia according to European LeukemiaNet (ELN) guidelines. We validated and compared the 2022 ELN risk classification in a real-life cohort of 546 intensively and 379 non-intensively treated patients. Among fit patients, those aged >= 65 years old showed worse OS than younger regardless risk classification. Compared with the 2017 classification, 14.5% of fit patients changed the risk with the 2022 classification, increasing the high-risk group from 44.3% to 51.8%. 3.7% and 0.9% FLT3-ITD mutated patients were removed from the favorable and adverse 2017 categories respectively to 2022 intermediate risk group. We suggest that midostaurin therapy could be a predictor for 3 years OS (85.2% with vs. 54.8% without midostaurin, P = 0.04). Forty-seven (8.6%) patients from the 2017 intermediate group were assigned to the 2022 adverse-risk group as they harbored myelodysplasia (MDS)-related mutations. Patients with one MDS-related mutation did not reach median OS, while patients with >= 2 mutations had 13.6 months median OS (P = 0.002). Patients with TP53 +/- complex karyotype or inv(3) had a dismal prognosis (7.1 months median OS). We validate the prognostic utility of the 2022 ELN classification in a real-life setting providing supportive evidences to improve risk stratification guidelines.
publishDate 2023
dc.date.none.fl_str_mv 2023
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://isabial.portalinvestigacion.com/publicaciones9741
https://www.nature.com/articles/s41408-023-00835-5
url https://isabial.portalinvestigacion.com/publicaciones9741
https://www.nature.com/articles/s41408-023-00835-5
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv SPRINGERNATURE
publisher.none.fl_str_mv SPRINGERNATURE
dc.source.none.fl_str_mv Blood Cancer Journal
ISSN: 20445385
reponame:r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname:Instituto de Investigación Biomédica y Sanitaria de Alicante (ISABIAL)
instname_str Instituto de Investigación Biomédica y Sanitaria de Alicante (ISABIAL)
reponame_str r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
collection r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869417941309587456
score 15.812429

Registos relacionados